Masao Nakata
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Masao Nakata has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Shinsuke Saisho
Department of General Thoracic Surgery, Kawasaki Medical School, Kurashiki, Okayama, Japan
6 shared publications- Katsuhiko Shimizu
Department of General Thoracic Surgery, Kawasaki Medical School, Kurashiki, Okayama, Japan
5 shared publications Ai Maeda
Department of General Thoracic Surgery, Kawasaki Medical School, Kurashiki, Okayama, Japan
3 shared publicationsMotohiro Yamashita
Okayama University Thoracic Surgery Study Group (OUTSSG), Okayama, Japan
3 shared publications- Riki Okita
Department of Thoracic Surgery, National Hospital Organization Yamaguchi Ube Medical Center, Ube, Japan
3 shared publications Shinichi Toyooka
Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
3 shared publications
Latest Publications
- Open Access
- 10 October 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (2) , 2301-2310
Total thymectomy is oncologically superior to partial thymectomy in patients with thymic carcinoma: insights from a multicenter real-world data analysis
Background: Although total thymectomy has been the standard surgical approach for thymic epithelial tumors, an increasing number of recent reports suggest that partial thymectomy for early-stage thymomas may yield outcomes comparable to those of total thymectomy. However, whether partial thymectomy is a viable alternative for thymic carcinoma remains unclear. Materials and methods: A total of 106 patients with thymic carcinoma underwent curative intended resection at 19 institutions between January 2010 and December 2021. Excluding 14 patients with incomplete resection, 92 patients with thymic carcinoma who underwent total ( n = 73) or partial thymectomy ( n = 19) were compared. Overall survival (OS) and recurrence-free survival (RFS) were analyzed using Kaplan–Meier curves and Cox proportional hazard models. Overlap weighting was applied to adjust for potential confounding factors. Results: Among patients with clinical stage I disease, 79.3% were upstaged to stage II or higher postoperatively. Unadjusted analyses revealed no statistically significant differences in OS and RFS between the total and partial thymectomy groups, although a trend toward poorer outcomes in the partial thymectomy group was observed. After overlap weighting, partial thymectomy was associated with significantly poorer OS ( P = 0.0027) and higher recurrence risk ( P < 0.0001). Early postoperative recurrence occurred more frequently in the partial thymectomy group. Conclusion: Partial thymectomy was associated with significantly worse survival and recurrence outcomes in thymic carcinoma. Given the limitations of preoperative diagnosis, total thymectomy should remain the preferred surgical approach for undiagnosed thymic epithelial tumors to achieve optimal oncologic control and minimize the risk of recurrence.
- 10 October 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (2) , 2301-2310
Open AccessTotal thymectomy is oncologically superior to partial thymectomy in patients with thymic carcinoma: insights from a multicenter real-world data analysis
Background: Although total thymectomy has been the standard surgical approach for thymic epithelial tumors, an increasing number of recent reports suggest that partial thymectomy for early-stage thymomas may yield outcomes comparable to those of total thymectomy. However, whether partial thymectomy is a viable alternative for thymic carcinoma remains unclear. Materials and methods: A total of 106 patients with thymic carcinoma underwent curative intended resection at 19 institutions between January 2010 and December 2021. Excluding 14 patients with incomplete resection, 92 patients with thymic carcinoma who underwent total ( n = 73) or partial thymectomy ( n = 19) were compared. Overall survival (OS) and recurrence-free survival (RFS) were analyzed using Kaplan–Meier curves and Cox proportional hazard models. Overlap weighting was applied to adjust for potential confounding factors. Results: Among patients with clinical stage I disease, 79.3% were upstaged to stage II or higher postoperatively. Unadjusted analyses revealed no statistically significant differences in OS and RFS between the total and partial thymectomy groups, although a trend toward poorer outcomes in the partial thymectomy group was observed. After overlap weighting, partial thymectomy was associated with significantly poorer OS ( P = 0.0027) and higher recurrence risk ( P < 0.0001). Early postoperative recurrence occurred more frequently in the partial thymectomy group. Conclusion: Partial thymectomy was associated with significantly worse survival and recurrence outcomes in thymic carcinoma. Given the limitations of preoperative diagnosis, total thymectomy should remain the preferred surgical approach for undiagnosed thymic epithelial tumors to achieve optimal oncologic control and minimize the risk of recurrence.
- Open Access
- 1 October 2025
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 17, 2319-2336
Comparative Diagnostic Performance of Digital Versus Analog PET/CT for Lymph Node Metastases and Glut-1 Correlation in Resected Non-Small Cell Lung Cancer
Background: Recent innovations in technology have significantly advanced the imaging capabilities of positron emission tomography/computed tomography (PET/CT). Digital PET/CT provides sensitive and high-resolution imaging and can improve the detection of small lesions as compared to conventional (analog) PET/CT. This study aimed to compare the diagnostic performance of digital versus analog PET/CT for detecting lymph node metastases and to assess the maximum standardized uptake (SUVmax) values in patients with resected non-small cell lung cancer (NSCLC). Methods: We enrolled a total of 103 patients with lung adenocarcinoma or squamous cell carcinoma who had undergone preoperative PET/CT in either analog or digital scanners. The primary endpoint was comparison of the diagnostic performance of the two modalities for lymph node metastasis, and the secondary endpoints were comparison of the SUVmax values and correlation of the SUVmax values with the Glut-1 (glucose transporter type 1) expression. Results: Of the 103 patients enrolled in the study, 61 had undergone analog PET/CT, and 42 had undergone digital PET/CT. Significantly higher SUVmax values on digital as compare with analog PET/CT were obtained for cT1b tumors (D/A ratio = 3.42, p = 0.002) as well as cT1c tumors (D/A ratio = 2.10, p < 0.001). However, no significant difference in SUVmax values between the two types of PET/CT was obtained for tumors exceeding 3.0 cm in diameter. A stronger correlation was found between tumor Glut-1 expression and the SUVmax values obtained digital PET/CT as compared with the values obtained with analog PET/CT. Digital PET/CT also showed a higher sensitivity (71.4% vs 37.5%) for detecting lymph node metastases, although the specificity was slightly lower (88.6% vs 96.2%), and the overall accuracy was comparable (85.7% vs 88.5%) between the two types of scanners. False-positive lymph nodes on digital PET/CT were obtained in conditions such as pneumoconiosis and anthracosis, while false-negatives results were obtained in conditions such as micrometastases and/or low lymph node Glut-1 expression. Conclusion: These results suggest that digital PET/CT shows improved diagnostic sensitivity and that the results of digital PET/CT are better correlated with tumor metabolic activity, which results in improved detection of lymph node metastases. These results support the clinical usefulness of digital PET/CT for optimizing perioperative strategies and increasing diagnostic confidence in the management of NSCLC. Future multicenter prospective studies and a standardized redefinition of SUVmax are urgently needed to validate our findings and to establish more reliable clinical application of digital PET/CT in patients with lung cancer.
- 1 October 2025
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 17, 2319-2336
Open AccessComparative Diagnostic Performance of Digital Versus Analog PET/CT for Lymph Node Metastases and Glut-1 Correlation in Resected Non-Small Cell Lung Cancer
Background: Recent innovations in technology have significantly advanced the imaging capabilities of positron emission tomography/computed tomography (PET/CT). Digital PET/CT provides sensitive and high-resolution imaging and can improve the detection of small lesions as compared to conventional (analog) PET/CT. This study aimed to compare the diagnostic performance of digital versus analog PET/CT for detecting lymph node metastases and to assess the maximum standardized uptake (SUVmax) values in patients with resected non-small cell lung cancer (NSCLC). Methods: We enrolled a total of 103 patients with lung adenocarcinoma or squamous cell carcinoma who had undergone preoperative PET/CT in either analog or digital scanners. The primary endpoint was comparison of the diagnostic performance of the two modalities for lymph node metastasis, and the secondary endpoints were comparison of the SUVmax values and correlation of the SUVmax values with the Glut-1 (glucose transporter type 1) expression. Results: Of the 103 patients enrolled in the study, 61 had undergone analog PET/CT, and 42 had undergone digital PET/CT. Significantly higher SUVmax values on digital as compare with analog PET/CT were obtained for cT1b tumors (D/A ratio = 3.42, p = 0.002) as well as cT1c tumors (D/A ratio = 2.10, p < 0.001). However, no significant difference in SUVmax values between the two types of PET/CT was obtained for tumors exceeding 3.0 cm in diameter. A stronger correlation was found between tumor Glut-1 expression and the SUVmax values obtained digital PET/CT as compared with the values obtained with analog PET/CT. Digital PET/CT also showed a higher sensitivity (71.4% vs 37.5%) for detecting lymph node metastases, although the specificity was slightly lower (88.6% vs 96.2%), and the overall accuracy was comparable (85.7% vs 88.5%) between the two types of scanners. False-positive lymph nodes on digital PET/CT were obtained in conditions such as pneumoconiosis and anthracosis, while false-negatives results were obtained in conditions such as micrometastases and/or low lymph node Glut-1 expression. Conclusion: These results suggest that digital PET/CT shows improved diagnostic sensitivity and that the results of digital PET/CT are better correlated with tumor metabolic activity, which results in improved detection of lymph node metastases. These results support the clinical usefulness of digital PET/CT for optimizing perioperative strategies and increasing diagnostic confidence in the management of NSCLC. Future multicenter prospective studies and a standardized redefinition of SUVmax are urgently needed to validate our findings and to establish more reliable clinical application of digital PET/CT in patients with lung cancer.
- Open Access
- 1 July 2025
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 17, 1477-1486
Predictive Value of Tumor ERCC1 Expression for Treatment Outcomes After Adjuvant Chemotherapy in Patients with Completely Resected Non-Small Cell Lung Cancer
To evaluate the predictive value of tumor expression of the excision repair cross-complementation group 1 gene (ERCC1) for the treatment outcomes after platinum-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer (NSCLC). In this study, we conducted immunohistochemical analysis using a mouse monoclonal anti-ERCC1 antibody (clone 8F1) of operative specimens obtained from 238 patients enrolled in the SLCG0401 study which compared paclitaxel plus carboplatin (CBDCA+PTX) with uracil-tegafur (UFT) as adjuvant chemotherapy for stage IB-IIIA NSCLC. The overall survival (OS) of the patients was compared according to the ERCC1 expression status and adjuvant chemotherapy employed. Of the 238 specimens, 102 (42.9%) showed a positive result for ERCC1 expression. There were no significant differences in the patient characteristics or OS between the tumor ERCC1-positive and -negative patient groups. Among the patients with ERCC1-negative tumors, there was no significant difference in the survival between patient groups treated with CBDCA+PTX and UFT (HR=0.932, 95% CI: 0.52–1.67, p=0.814). However, among the patients with ERCC1-positive tumors, CBDCA+PTX treatment tended to yield an inferior outcome, in terms of the OS, as compared with UFT treatment (HR=1.852, 95% CI: 0.92–3.73, p=0.080). Multivariate analysis showed that ERCC1 expression was not an independent predictor of the OS following CBDCA+PTX treatment in completely resected NSCLC patients. In completely resected NSCLC patients with positive tumor ERCC1 expression, adjuvant CBDCA+PTX treatment tended to yield an inferior outcome as compared with UFT treatment in terms of the OS. However, immunohistochemical analysis with the 8F1 antibody cannot be used for clinical decision making at this point.
- 1 July 2025
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 17, 1477-1486
Open AccessPredictive Value of Tumor ERCC1 Expression for Treatment Outcomes After Adjuvant Chemotherapy in Patients with Completely Resected Non-Small Cell Lung Cancer
To evaluate the predictive value of tumor expression of the excision repair cross-complementation group 1 gene (ERCC1) for the treatment outcomes after platinum-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer (NSCLC). In this study, we conducted immunohistochemical analysis using a mouse monoclonal anti-ERCC1 antibody (clone 8F1) of operative specimens obtained from 238 patients enrolled in the SLCG0401 study which compared paclitaxel plus carboplatin (CBDCA+PTX) with uracil-tegafur (UFT) as adjuvant chemotherapy for stage IB-IIIA NSCLC. The overall survival (OS) of the patients was compared according to the ERCC1 expression status and adjuvant chemotherapy employed. Of the 238 specimens, 102 (42.9%) showed a positive result for ERCC1 expression. There were no significant differences in the patient characteristics or OS between the tumor ERCC1-positive and -negative patient groups. Among the patients with ERCC1-negative tumors, there was no significant difference in the survival between patient groups treated with CBDCA+PTX and UFT (HR=0.932, 95% CI: 0.52–1.67, p=0.814). However, among the patients with ERCC1-positive tumors, CBDCA+PTX treatment tended to yield an inferior outcome, in terms of the OS, as compared with UFT treatment (HR=1.852, 95% CI: 0.92–3.73, p=0.080). Multivariate analysis showed that ERCC1 expression was not an independent predictor of the OS following CBDCA+PTX treatment in completely resected NSCLC patients. In completely resected NSCLC patients with positive tumor ERCC1 expression, adjuvant CBDCA+PTX treatment tended to yield an inferior outcome as compared with UFT treatment in terms of the OS. However, immunohistochemical analysis with the 8F1 antibody cannot be used for clinical decision making at this point.
- Open Access
- 1 July 2024
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 16, 965-976
Predictive Value of PERCIST for Locally Advanced Non-Small Cell Lung Cancer Treated with Preoperative Induction Therapy – A Multicenter Study in Japan
Background: Induction therapy followed by surgery is recommended as an alternative treatment strategy for locally advanced non-small cell lung cancer (NSCLC). Patients who achieve pathologic response after induction therapy have better outcomes than non-responders; therefore, therapeutic response must be evaluated. Recently, new approaches for monitoring therapeutic responses, which are based on 18F‐Fluorodeoxyglucose positron emission tomography (FDG‐PET), have been developed. In this study, we evaluated the predictive value of Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST), which uses standardized uptake values corrected for lean body mass (SUL) and total lesion glycolysis (TLG). Methods: A total of 130 patients in the Setouchi Lung Cancer Group who underwent FDG-PET imaging before and after induction therapy prior to a planned surgical resection for NSCLC between 2007 and 2016 were studied retrospectively. The pathologic responses of the primary lung tumors and metastatic lymph nodes were compared with their responses based on evaluation using PERCIST. Results: Postoperative pathologic studies revealed pathologic complete response (pCR) in 42 (32.3%) patients. PERCIST was significantly correlated with pathologic response (p < 0.001). The sensitivity, specificity, and accuracy of PERCIST for predicting pCR were 16.7% (7/42), 88.6% (78/88), and 65.4% (85/130), respectively. Patients with pCR had significantly higher reduction rates in SULpeak for both primary lung tumors and metastatic lymph nodes and TLG for primary tumors than non-responders. In a multivariate Cox regression analysis, tumor site in upper lobes, reduction rate of TLG in primary tumor, and pathologic N0 were independent predictors of favorable recurrence-free survival (RFS). Conclusion: Our study suggested that PERCIST, especially the rate of TLG reduction rate, are useful to predict the pathological response and prognosis after induction therapy. Although improvement is necessary, PERCIST can be a promising method of the post-induction status in lung cancer. Further research is needed to confirm our findings.
- 1 July 2024
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 16, 965-976
Open AccessPredictive Value of PERCIST for Locally Advanced Non-Small Cell Lung Cancer Treated with Preoperative Induction Therapy – A Multicenter Study in Japan
Background: Induction therapy followed by surgery is recommended as an alternative treatment strategy for locally advanced non-small cell lung cancer (NSCLC). Patients who achieve pathologic response after induction therapy have better outcomes than non-responders; therefore, therapeutic response must be evaluated. Recently, new approaches for monitoring therapeutic responses, which are based on 18F‐Fluorodeoxyglucose positron emission tomography (FDG‐PET), have been developed. In this study, we evaluated the predictive value of Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST), which uses standardized uptake values corrected for lean body mass (SUL) and total lesion glycolysis (TLG). Methods: A total of 130 patients in the Setouchi Lung Cancer Group who underwent FDG-PET imaging before and after induction therapy prior to a planned surgical resection for NSCLC between 2007 and 2016 were studied retrospectively. The pathologic responses of the primary lung tumors and metastatic lymph nodes were compared with their responses based on evaluation using PERCIST. Results: Postoperative pathologic studies revealed pathologic complete response (pCR) in 42 (32.3%) patients. PERCIST was significantly correlated with pathologic response (p < 0.001). The sensitivity, specificity, and accuracy of PERCIST for predicting pCR were 16.7% (7/42), 88.6% (78/88), and 65.4% (85/130), respectively. Patients with pCR had significantly higher reduction rates in SULpeak for both primary lung tumors and metastatic lymph nodes and TLG for primary tumors than non-responders. In a multivariate Cox regression analysis, tumor site in upper lobes, reduction rate of TLG in primary tumor, and pathologic N0 were independent predictors of favorable recurrence-free survival (RFS). Conclusion: Our study suggested that PERCIST, especially the rate of TLG reduction rate, are useful to predict the pathological response and prognosis after induction therapy. Although improvement is necessary, PERCIST can be a promising method of the post-induction status in lung cancer. Further research is needed to confirm our findings.
- Open Access
- 1 May 2019
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. ume 15, 605-612
Comparative study of the PD-L1 expression and CD8+ tumor-infiltrating lymphocyte between surgically resected and matched re-biopsy specimens in recurrent non-small cell lung cancer
Introduction: Numerous studies conducted until date have reported that the chemotherapy regimen could affect the programmed cell death ligand 1 (PD-L1) expression status in patients with non-small cell lung cancer (NSCLC). Materials and methods: A total of 36 NSCLC patients for whom both the surgically resected specimens of the primary tumors and re-biopsy specimens of the recurrent tumors were available were enrolled in this study. The PD-L1 expression status and tumor-infiltrating CD8-positive T lymphocytes (CD8+TILs) count were measured in paired samples by immunohistochemistry. The concordance rate in the tumor immune microenvironment (TIME) classification based on the PD-L1 expression status and CD8+TILs count was analyzed. Results: While the PD-L1 expression levels were similar between the surgical and re-biopsy specimens in 77.8% of cases, in 16.7% of cases, the expression levels were higher in the re-biopsy specimens. When the analysis was confined to patients who had received platinum-based chemotherapy, the percentage increased to 42.9%. The TIME classification changed in the re-biopsy specimens as compared to the surgical specimens in one-third of the patients, especially in those who had received chemotherapy previously. The TIME classification in the re-biopsy specimens more closely resembled that in the metastatic lymph nodes as compared to that in the primary tumor. Conclusion: In patients with recurrent NSCLC, especially those who have received chemotherapy previously, a recent re-biopsy sample is required to determine whether PD-1/PD-L1 inhibitors should be used for treatment or not.
- 1 May 2019
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. ume 15, 605-612
Open AccessComparative study of the PD-L1 expression and CD8+ tumor-infiltrating lymphocyte between surgically resected and matched re-biopsy specimens in recurrent non-small cell lung cancer
Introduction: Numerous studies conducted until date have reported that the chemotherapy regimen could affect the programmed cell death ligand 1 (PD-L1) expression status in patients with non-small cell lung cancer (NSCLC). Materials and methods: A total of 36 NSCLC patients for whom both the surgically resected specimens of the primary tumors and re-biopsy specimens of the recurrent tumors were available were enrolled in this study. The PD-L1 expression status and tumor-infiltrating CD8-positive T lymphocytes (CD8+TILs) count were measured in paired samples by immunohistochemistry. The concordance rate in the tumor immune microenvironment (TIME) classification based on the PD-L1 expression status and CD8+TILs count was analyzed. Results: While the PD-L1 expression levels were similar between the surgical and re-biopsy specimens in 77.8% of cases, in 16.7% of cases, the expression levels were higher in the re-biopsy specimens. When the analysis was confined to patients who had received platinum-based chemotherapy, the percentage increased to 42.9%. The TIME classification changed in the re-biopsy specimens as compared to the surgical specimens in one-third of the patients, especially in those who had received chemotherapy previously. The TIME classification in the re-biopsy specimens more closely resembled that in the metastatic lymph nodes as compared to that in the primary tumor. Conclusion: In patients with recurrent NSCLC, especially those who have received chemotherapy previously, a recent re-biopsy sample is required to determine whether PD-1/PD-L1 inhibitors should be used for treatment or not.
- Open Access
- 30 July 2018
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 38 (8) , 4637-4644
Impact of COX2 Inhibitor for Regulation of PD-L1 Expression in Non-small Cell Lung Cancer
Background/Aim: There is no clear evidence in the literature regarding the regulation of programmed cell death-ligand 1 (PD-L1) expression by cyclo-oxygenase-2 (COX2). In this study, whether PD-L1 expression was regulated by COX2 activity was examined in vitro. Materials and Methods: Resected lung cancer specimens were analyzed for PD-L1 and COX2 expression by immunohistochemical analysis. Next, co-localization of PD-L1 and COX2 expression was analyzed by double-fluorescence staining. Lastly, the effect of COX2 inhibition on the expression of PD-L1 was examined using lung cancer cell lines. Results: PD-L1 expression was significantly correlated with COX2 expression in the resected specimens. The majority of cancer cells that expressed PD-L1 also co-expressed COX2. However, treatment of lung cancer cell lines with a COX2 inhibitor had no impact on PD-L1 expression. Conclusion: Our results suggest that COX2 inhibition might have no effect on the usage of immune checkpoint inhibitors in lung cancer treatment.
- 30 July 2018
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 38 (8) , 4637-4644
Open AccessImpact of COX2 Inhibitor for Regulation of PD-L1 Expression in Non-small Cell Lung Cancer
Background/Aim: There is no clear evidence in the literature regarding the regulation of programmed cell death-ligand 1 (PD-L1) expression by cyclo-oxygenase-2 (COX2). In this study, whether PD-L1 expression was regulated by COX2 activity was examined in vitro. Materials and Methods: Resected lung cancer specimens were analyzed for PD-L1 and COX2 expression by immunohistochemical analysis. Next, co-localization of PD-L1 and COX2 expression was analyzed by double-fluorescence staining. Lastly, the effect of COX2 inhibition on the expression of PD-L1 was examined using lung cancer cell lines. Results: PD-L1 expression was significantly correlated with COX2 expression in the resected specimens. The majority of cancer cells that expressed PD-L1 also co-expressed COX2. However, treatment of lung cancer cell lines with a COX2 inhibitor had no impact on PD-L1 expression. Conclusion: Our results suggest that COX2 inhibition might have no effect on the usage of immune checkpoint inhibitors in lung cancer treatment.
- Open Access
- 23 March 2013
- Published by Springer Nature in General Thoracic and Cardiovascular Surgery
- Vol. 62 (4) , 252-254
A case report of intrapulmonary schwannoma
A 38-year-old man without any symptoms was admitted to our institution because of an abnormal shadow found incidentally on a chest X-ray. Chest computed tomography showed a round mass in the lingular segment of the left upper lobe. Lingular segmentectomy was performed, and the histopathological diagnosis was intrapulmonary schwannoma. Immunohistochemical staining revealed a positive result for S-100 protein and negative results for CD34 and desmin. We report this case of intrapulmonary schwannoma, which is extremely rare.
- 23 March 2013
- Published by Springer Nature in General Thoracic and Cardiovascular Surgery
- Vol. 62 (4) , 252-254
Open AccessA case report of intrapulmonary schwannoma
A 38-year-old man without any symptoms was admitted to our institution because of an abnormal shadow found incidentally on a chest X-ray. Chest computed tomography showed a round mass in the lingular segment of the left upper lobe. Lingular segmentectomy was performed, and the histopathological diagnosis was intrapulmonary schwannoma. Immunohistochemical staining revealed a positive result for S-100 protein and negative results for CD34 and desmin. We report this case of intrapulmonary schwannoma, which is extremely rare.